The purpose of this study was to determine the PGE(2) concentration in natu
rally-occurring cancer in pet dogs and in canine cancer cell lines in order
to identity specific types of canine cancer with high PGE(2) production wh
ich could serve as preclinical models to evaluate anticancer strategies tar
geting PGE(2). PGE(2) concentrations were measured by enzyme immunoassay in
canine melanoma, soft tissue sarcoma, transitional cell carcinoma, osteosa
rcoma, and prostatic carcinoma cell lines; in 80 canine tumor tissue sample
s including oral melanoma (MEL), oral squamous cell carcinoma (SCC), transi
tional cell carcinoma of the urinary bladder (TCC), lymphoma (LSA), mammary
carcinoma (MCA), osteosarcoma (OSA), prostatic carcinoma (PCA); and in cor
responding normal organ tissues. High concentrations of PGE(2) (range 400-3
300 pg/10(4) cells) were present in cell culture medium from the transition
al cell carcinoma, prostatic carcinoma, and osteosarcoma cell lines. PGE(2)
concentrations in tu mor tissues were elevated (tumor PGE(2) concentration
> mean+ 2x sd PGE(2) concentration of normal organ tissue) in 21/22 TCC, 5
/6 PCA, 7/10 SCC, 5/10 MEL, 3/8 MCA, 4/15 OSA, and 0/9 LSA. Results of this
study will help guide future investigations of anticancer therapies that t
arget cyclooxygenase and PGE(2). (C) 2001 Harcourt Publishers Ltd.